Corcept Therapeutics has shifted gear: the stock is up 18% on the week and 38% over the past month, and this time the shorts are finally moving with it.
The most meaningful change since last week's note is in short positioning. Short interest has dropped to 9.1% of free float — down from the 12.2% level that held stubbornly through most of May. That is a genuine retreat, not noise. A week ago, the prior note flagged the divergence between a rallying stock and shorts refusing to cover. That divergence has now partially closed, with roughly 1.5 million shares unwound from the short book over the past week alone. The borrow market reflects the shift: cost to borrow has nudged up to 0.59% — still negligible in absolute terms, but up 17% on the week as covering demand ticks higher. Availability remains extraordinarily loose at 739%, down from around 890% last week, but still well above any level that signals squeeze pressure. Shorts are reducing, not panicking.
Options positioning tells an even cleaner bullish story. The put/call ratio is running at 0.26, almost a full standard deviation below its 20-day average of 0.42. Two weeks ago that ratio sat north of 0.60. The shift is dramatic and has held: call-side demand has dominated for nearly three weeks straight, with the PCR now approaching its 52-week low of 0.25. The options market is not hedging this move — it is participating in it.
The Street is racing to catch up. In the past week alone, Canaccord Genuity raised its target to $135 and HC Wainwright lifted to $95, both maintaining Buy ratings. That followed UBS upgrading the stock to Buy on May 13 with a $72 target — a target the stock has already blown past at $71.20. The consensus mean sits at $88, which is now fractionally below the current price, suggesting further target upgrades are likely in train. The bull case centres on the commercial ramp of Lifyorli and the expected resubmission of relacorilant for a second indication by year-end 2026. The bear case is more nuanced than outright pessimism: the company posted a net loss of $0.30 per share in Q1, and R&D expenses are set to climb with the resubmission. Factor scores lean firmly constructive — EPS momentum ranks in the 97th percentile on a 30-day basis and the 96th on a 90-day view, with analyst recommendation divergence in the 91st percentile.
Insider activity adds a layer of complexity. CEO and founder Joseph Belanoff sold ~12,800 shares on June 1 at $69.74, and division president Sean Maduck sold a combined ~75,000 shares on May 27. Those are material clip sizes, even if they likely reflect pre-arranged plans. The 90-day net insider balance across all transactions is technically positive at roughly 325,000 shares — largely because director George Baker bought ~75,800 shares in March at $33. The pattern is one of a founder and senior management trimming into strength at prices meaningfully above where Baker bought. Institutional flows are broadly stable, with BlackRock and State Street both adding modestly in their latest reported periods.
Earnings are next scheduled for July 29. The last print on April 30 delivered a 10% single-day move and a further 9.5% over the following week. The print before that — May 6 — was nearly flat on the day. The July report will be the first to reflect a fuller quarter of Lifyorli commercial traction, and the resubmission timeline for relacorilant is the number the market is likely to interrogate hardest.
See the live data behind this article on ORTEX.
Open CORT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
